CONFIDENTIAL DOCUMENT
17 July 2000
PROFESSIONAL SERVICES and CONFIDENTIALITY
AGREEMENT between
Lexon, Inc.
&
DIAGNOSTIC ONCOLOGY CRO, Inc.
PARTIES
The parties to this Professional Services and Confidentiality Agreement are
Lexon, Inc. and its affiliates, subsidiaries and the like ("LEXON") located in
Tulsa, Oklahoma, and DIAGNOSTIC ONCOLOGY CRO, Inc. ("DOCRO"), located in
Seymour, Connecticut.
PURPOSES
LEXON is engaged in the business of developing medical diagnostic products for
distribution to the biotechnology, healthcare, medical diagnostic, medical
device, and therapeutic industries, in particular, in vitro diagnostic assays
for determining the amount of ebaf tumor marker in the tissues, blood, other
fluids, and other specimen matrices of mammals.
DOCRO is engaged in providing technology assessment, technology development, and
laboratory and clinical trial services to medical device developers, in
particular, providing technology assessment and technology development services
related to the development and commercialization of in vitro diagnostic assays
for determining the amount of tumor markers or other analytes in the tissues,
blood, other fluids, and other specimen matrices of mammals.
LEXON wishes to engage DOCRO to conduct a technology assessment and development
program for LEXON's ebaf tumor marker technology. This program requires DOCRO to
assess the current technical and clinical performance of the existing ebaf
reagents as provided by Xx. X.Xxxxxxxxxx, North Shore University Hospital, North
Shore, New York, then for DOCRO to develop purified ebaf antigens (native and
recombinant protein and various peptides, for all four known forms of ebaf
protein expressed in human tissue (precursor ebaf protein having an approximate
molecular weight (including native glycosylation) of 42 kDa, and three clipped
forms of this precursor having approximate molecular weights (including native
glycosylation) of 34 kDa, 26 kDa, and 14 kDa) and then to raise a variety of
monoclonal antibodies and polyclonal antibodies to these various antigens to
determine if any ebaf protein is overexpressed in the tissue, blood, other
fluids, and other specimen matrices from humans diagnosed with colorectal cancer
when compared to similar specimens from apparently healthy, normal humans and
from a variety of humans diagnosed with other malignant diseases or
non-malignant diseases. Further, if an ebaf protein is determined by DOCRO to be
overexpressed in malignant disease and not in non-malignant disease or
apparently healthy normals and LEXON agrees, DOCRO shall develop an enzyme
immunoassay for such ebaf protein to confirm the results in the blood or other
fluid specimen matrix of a statistically significant number (maximum of 400)
patients.
In consideration of the mutual promises specified below, DOCRO offers to provide
technology assessment and technology development professional services to LEXON
in accordance with the terms and conditions of this Agreement, which LEXON
accepts.
DEFINITIONS
"Confidential & Proprietary Information" shall include any information owned by
any party, as well as information developed by DOCRO in connection with services
performed under this Agreement which shall be considered LEXON's confidential
information, whether or not such information is in oral, written or other form,
or was denominated or specifically identified as confidential when disclosed,
observed or developed. Such information may include, but is not limited to
commercial or technological plans, customer lists, discoveries, inventions,
know-how, processes, software, suppliers, trade secrets, as well as any
analytical chemical or biological specimens or prototypes.
"DOCRO" shall mean the entity identified in the PARTIES section, including any
entities affiliated with DOCRO, including but not limited to DOCRO's employees,
agents, officers or principals, and, its contractors.
"LEXON" shall mean the entity identified in the PARTIES section, including any
entities affiliated with LEXON (or any purchaser of substantially all of LEXON's
assets), including but not limited to LEXON's employees, agents, officers or
principals, and, its contractors.
"PRODUCTS" shall mean LEXON's ebaf technology used for the assessment and/or
development of an in vitro diagnostic assay to determine if any ebaf protein is
overexpressed in the tissue, blood, other fluids, and other specimen matrices
from humans diagnosed with colorectal cancer when compared to similar specimens
from apparently healthy, normal humans and from a variety of humans diagnosed
with other malignant diseases or non-malignant diseases, including any native or
recombinant ebaf protein or peptide antigen in any form, and antibody raised to
any native or recombinant ebaf protein or peptide antigen.
--2 of 14--
TERMS AND CONDITIONS
1.0 Services to be Provided by DOCRO
1.1. Technology Assessment - DOCRO shall assess for LEXON the current technical
and clinical performance of the existing ebaf reagents as provided by LEXON and
the inventor, Xx. X.Xxxxxxxxxx, North Shore University Hospital, North Shore,
New York.
1.2. Technology Development -DOCRO shall develop purified ebaf antigens (native
and recombinant protein and various peptides, for all four known forms of ebaf
protein expressed in human tissue (precursor ebaf protein having an approximate
molecular weight (including native glycosylation) of 42 kDa, and three clipped
forms of this precursor having approximate molecular weights (including native
glycosylation) of 34 kDa, 26 kDa, and 14 kDa) and then to raise a variety of
monoclonal antibodies and polyclonal antibodies to these various antigens to
determine if any ebaf protein is overexpressed in the tissue, blood, other
fluids, and other specimen matrices from humans diagnosed with colorectal cancer
when compared to similar specimens from apparently healthy, normal humans and
from a variety of humans diagnosed with other malignant diseases or
non-malignant diseases. Further, if an ebaf protein is determined by DOCRO to be
overexpressed in malignant disease and not in non-malignant disease or
apparently healthy normals and LEXON agrees, DOCRO shall develop an enzyme
immunoassay for such ebaf protein to confirm the results in the blood or other
fluid specimen matrix of a statistically significant number (maximum of 400)
patients.
1.3. Analysis and Reports - DOCRO shall provide to LEXON an analysis and written
report of the work performed with recommendations for the next steps to be taken
by DOCRO conducted in Section 1.1. and Section 1.2. on a bi-weekly basis from
the inception of the project. LEXON must provide written notification to DOCRO
within forty-eight (48) hours of the issuance of the report if LEXON desires
DOCRO not to perform the work that DOCRO recommends in the report. DOCRO shall
provide to LEXON a written report summarizing DOCRO's findings and activities
upon DOCRO's completion of the technology assessment portion of this Agreement
and upon termination of this Agreement.
1.4. The parties agree that DOCRO shall provide LEXON with its services under
this Agreement on a non-exclusive basis. Subject to the limitations of this
Agreement, DOCRO and LEXON may provide or obtain consulting and advisory
services to or from any third party.
1.5. Pursuant to the terms of this Agreement, DOCRO shall commence work
immediately upon receipt of a fully executed original of this Agreement and the
initial moneys set forth herein.
2.0 Term
2.1. The term of this Agreement shall commence on 8 August 2000, and shall
continue for a duration of one (1) year, but after DOCRO's completion of the
technology assessment portion of
--3 of 14--
this Agreement may be terminated at will by LEXON giving thirty (30) days
written notice to the other. In the event of such termination, LEXON's sole
obligation to DOCRO shall be to pay DOCRO any fees and expenses for services
either (i) rendered by the date of termination or (ii) at least partially
rendered and committed with respect to any case report from an investigator
working for DOCRO, such fees and expenses to be subtracted from the down payment
made by LEXON pursuant to Section 3.3. hereof. The balance shall be returned to
LEXON. In no event shall the amount due be greater than the amount set forth in
Section 3.
2.2. The confidentiality provision of Section 4.0 of this Agreement shall be in
force for a period of three (3) years from the effective date of this Agreement.
3.0 Compensation & Reimbursement
3.1. DOCRO shall be compensated by LEXON according to the terms of the attached
schedule (see Attachment A. - Estimated Fees, Milestone and Payment Schedule)
and this Section 3.0 for the conduct of the technology assessment and technology
development professional services rendered by DOCRO under the provisions of this
Agreement.
3.2. DOCRO shall be compensated by LEXON for the conduct of the technology
assessment and technology development professional services in total of one
million, four hundred, ninety-five thousand dollars (US $1,495,000.00). The
first three (3) fully creditable and non-refundable payments to DOCRO totaling
five hundred, fifty thousand dollars (US $550,000.00) as described in this
section of the Agreement and in any attachment to this Agreement are made to
DOCRO for the conduct of the technology assessment portion of this Agreement.
The first payment to DOCRO shall be a fully creditable, non-refundable advance
payment of one hundred thousand dollars (US $100,000.00) upon execution of this
Agreement. The second payment to DOCRO shall be a fully creditable,
non-refundable payment of two hundred, fifty thousand dollars (US $250,000.00)
thirty (30) days after the date of execution of this contract. The third payment
to DOCRO shall be a fully creditable, non-refundable payment of two hundred
thousand dollars (US $200,000.00) sixty (60) days after the execution date of
this Agreement. The basis for these amounts and the dates for additional
payments to be made by LEXON to DOCRO are set forth in Attachment A. - Estimated
Fees, Milestone and Payment Schedule. Such payments shall be made by wire
transfer to DOCRO's bank account: People's Bank of Connecticut, Bridgeport,
Connecticut - Bank Routing Number 000000000, Account Number 014-0000000. The
aggregate amount of the three advance payments, five hundred, fifty thousand
dollars (US $550,000.00) shall be subtracted from the total payment due to DOCRO
hereunder.
3.3. DOCRO shall xxxx LEXON for the remaining balance of nine hundred,
forty-five thousand dollars (US $945,000.00) plus any additional expenses
approved by LEXON and incurred as described in Attachment A. - Estimated Fees,
Milestone and Payment Schedule for services rendered on this contract shall be
billed to LEXON according to Attachment A., such monies to be used by DOCRO for
the assay development portion of this Agreement. LEXON shall reimburse DOCRO on
a net fifteen (15) day basis, time commencing from submission to LEXON of
invoice and statement of work completed or expenses incurred. If timely payment
for invoiced
--4 of 14--
fees is not made, in addition to other remedies, DOCRO may impose and LEXON
shall pay, a late payment charge equal to one and one-half percent (1.5%) of the
overdue amount each month.
3.4. DOCRO will notify LEXON in writing within five (5) working days from the
effective date if the estimated fees and expenses for this project exceed one
million, four hundred, ninety-five thousand dollars (US $1,495,000.00) (Fee
Cap), including expenses described in Attachment A. - Estimated Fees, Milestone
and Payment Schedule, but not including additional expenses, in which case LEXON
may terminate the Agreement. DOCRO shall provide LEXON a written Project
Description & Estimate (PDE) describing the new aspects or tasks required to
complete the project. The Fee Cap shall not include any fees or expenses
applicable to any meeting with any person or group other than meetings with
LEXON or with Xx. X. Xxxxxxxxxx to review work performed and planned related to
the technology assessment and development of the ebaf tumor marker technology.
3.5. DOCRO shall not initiate any work the cost of which shall exceed the Fee
Cap prior to obtaining LEXON's written approval of a PDE. A PDE shall describe
the aspects of the project to be performed by DOCRO, including a description of
the specific personnel and other resources needed to perform the new tasks of
the project, the time or schedule needed to complete such tasks, and a proposed
schedule for project related payments. The Fee Cap shall be increased by the
amount of any approved PDE.
3.6. DOCRO shall ensure that all charges are allocated accurately to the
activity or project for which such charges were incurred, and are supported by
documents. The nature and purpose of all invoiced items shall be identified in
the supporting documents.
3.7. DOCRO shall be paid for reasonable and necessary business expenses that are
incurred by DOCRO in the course of performing the obligations of this Agreement
as described in this Agreement. Such costs may include, (but are not limited
to), the following: computer research; laboratory expenses; long distance
telephone and telefacsimile charges; postage, printing and courier charges; and
travel expenses, (including the cost of transportation, meals and lodging).
LEXON shall compensate DOCRO fully for all travel and living expenses that are
not described in Attachment A. but that either are agreed to by LEXON and are
incurred for site visits to the premises of LEXON, any clinical investigator,
any laboratory investigator, or any other location that may be requested or are
required in order for DOCRO to fulfill its obligations described in this
Agreement.
3.8. The cost to prepare any reagents, materials, or products by a third party
on behalf of DOCRO and LEXON shall be passed on to LEXON with an eighteen
percent (18%) additional xxxx-up by DOCRO. However, any equipment, materials,
consumables, or non-ebaf specific reagent paid for by LEXON shall become the
property of DOCRO upon the termination of this AGREEMENT.
--5 of 14--
4.0 Confidential & Proprietary Information
4.1. DOCRO and LEXON hereby agree with respect to Confidential & Proprietary
Information: (1) to maintain the confidentiality of any Confidential &
Proprietary Information disclosed; (2) not to make any disclosure of proprietary
or confidential information to any third party; (3) not to use Confidential &
Proprietary Information except for the Purposes contemplated in this Agreement,
unless such further use is specifically authorized in writing by the party who
has title to the information; (4) to protect the other's Confidential &
Proprietary Information whether in storage or in use, with the same degree of
care as is exercised to protect its own against public disclosure (but in no
case with any less degree than reasonable care); and (5) not to disclose
Confidential & Proprietary Information to any personnel other than those for
whom such knowledge is essential for the purposes contemplated in this
Agreement, and such disclosure to them shall be made only under conditions of
strict confidentiality.
4.2. The obligations in this Article shall not apply to Confidential &
Proprietary Information that a party can show by previously existing
documentation: (a) is in the public domain on the date of this Agreement; (b)
comes into the public domain other than through that party's fault or
negligence; (c) is obtained lawfully from a third party with full rights of
disclosure; (d) was known already to that party at the date of receipt of the
information pursuant to this Agreement; (e) becomes known independently to that
party without making use of any of the other party's Confidential & Proprietary
information.
4.3. If this Agreement expires or is terminated, then a receiving party shall
promptly return all Confidential & Proprietary Information, together with all
copies thereof, except for the retention of one copy for archival purposes. Upon
a written request, the parties shall respectively provide an accounting for the
disposition of all such documents or specimens, including a written
certification attesting to return of all such confidential information. The
parties shall return such items regardless of any claims against one another.
4.4. No party shall make any press release or other public announcement
concerning the terms or execution of this Agreement without prior written
consent of the other parties.
4.5. If a disclosure of Confidential & Proprietary Information prohibited by
this Agreement is specifically required by law or by court order, any party will
notify the other parties of such required disclosure and, if so requested, will
execute all necessary documents and provide all reasonable assistance necessary
to defend the other party's lawful right to prevent or limit such disclosure.
The notifying party shall be entitled reasonable compensation for assisting in
such a defense.
5.0 Warranties & Certifications
5.1. DOCRO warrants that it shall make its best efforts to evaluate and
demonstrate that the ebaf technology performs technically and clinically as
claimed by LEXON and by Xx. X. Xxxxxxxxxx, North Shore University Hospital,
North Shore, New York. However, DOCRO does
--6 of 14--
not guarantee that the current ebaf reagents or assay as run in DOCRO's
laboratory will meet or exceed the performance claims asserted by LEXON or by
Xx. X. Xxxxxxxxxx.
5.2. DOCRO does not guarantee that the ebaf reagents and assay to be developed
by DOCRO under the terms of this Agreement shall meet or exceed the claims of
LEXON nor does DOCRO guarantee that the developed assay provide sufficient
technical or clinical performance characteristics nor sufficient clinical
sensitivity and specificity to warrant additional assay development or
subsequent clinical trials, including any trial intended for submission to FDA
for LEXON to gain approval to market an ebaf assay in the United States of
America.
5.3. DOCRO certifies that all of its employees, agents and contractors are bound
by the provisions of this Agreement, that it has obtained written agreements
from such employees and agents that are consistent with the provisions of
Section 4.0 of this Agreement, and that it will obtain written agreements from
employees, agents and contractors who in the future will become associated with
the project contemplated in this Agreement.
5.4. DOCRO represents and certifies that it and its employees and agents have
all appropriate expertise, training, certifications, immunizations and equipment
to safely and lawfully handle any materials, perform any laboratory tests, or
enter into work areas which may be necessary for work performed under this
Agreement.
5.5. LEXON certifies that all of its employees, agents and contractors are bound
by the provisions of this Agreement, that it has obtained written agreements
from such employees and agents that are consistent with the provisions of
Section 4.0 of this Agreement, and that it will obtain written agreements from
employees, agents and contractors who in the future will become associated with
the project contemplated in this Agreement.
5.6. LEXON warrants that no danger, hazard, or the like is known with respect to
its PRODUCTS, other than those dangers known to be associated with infectious
blood samples.
5.7. LEXON and DOCRO warrant that the signatories to this Agreement are
authorized to execute this Agreement on behalf of the respective parties.
6.0 Modification of Agreement
6.1. No waiver or modification of this Agreement shall be valid, nor shall it be
offered or received in evidence in any proceeding, arbitration or litigation
between the parties arising out of or related to this Agreement, unless such
waiver or modification is in writing signed by authorized representatives of
both parties, particularly pointing out any provisions to be added, deleted, or
modified.
6.2. Unless expressly approved by the waiving party in accordance with Section
6.1., the failure of either party to enforce any provision of this Agreement
shall not be construed as a waiver or limitation of that party's rights to
subsequently enforce and compel strict compliance with every
--7 of 14--
provision of the Agreement. No waiver (express or implied) by either party of
any breach of this Agreement shall constitute a waiver of any other or
subsequent breach.
7.0 Assignment
This Agreement shall be binding on and inure to the benefit of each party, its
successors or assigns. No assignment shall be made by either party without the
express written consent of the other party except that LEXON may assign this
agreement to a purchaser of substantially all of the assets of LEXON.
8.0 Independent Contractor Status
8.1. It is expressly stipulated, agreed and understood among the parties that
the business relationship between DOCRO and LEXON shall be that of independent
contractors, and does not constitute a partnership, joint venture, agency or
contract of employment.
8.2. No party shall have the authority to make any statements, representations
or commitments of any kind, or to take any action that shall be binding on the
other, except as provided for herein or authorized in writing by the parties to
be bound.
8.3. DOCRO shall be responsible solely for provision of personnel, equipment,
and supplies, and, subject to the terms of this Agreement, for payment of
DOCRO's costs, suppliers, employees and contractors. In no case shall any party
have the authority, or represent themselves as having the authority, to bind
legally any other in contract, debt or otherwise.
9.0 Notice
9.1. Any notice required under this Agreement shall be deemed given only upon
receipt of any letter or instrument sent by certified mail, return receipt
requested, postage prepaid by the sender, by overnight courier or by personal
delivery, unless prior notice is tenured by the sender that a signed telefaxed
response followed by confirmation by mail will satisfy the terms of this
provision.
If to DOCRO: If to LEXON:
------------ ------------
Xx. Xxxxxx X. Xxxxxxx Xx. Xxxxxx X. Xxxxxxxx, Xx.
President and Chief Executive Officer Medical Director
DIAGNOSTIC ONCOLOGY CRO, Inc. Lexon, Inc.
00 Xxxxxxxx Xxxx 0000 Xxxxx Xxxx Xxxxxx, Xxxxx 000
Xxxxxxx, XX 00000 Xxxxx, XX 00000-0000
--8 of 14--
9.2. From time to time either party, by written notice to the other in
accordance with this Section 11.0, may designate different or alternative
addresses or manners of delivery that shall become the effective or alternative
addresses, or manner of delivery, for such party or project as so designated.
10.0 Entire Understanding
This Agreement contains the complete understanding between the parties as to
conducting the technology assessment and technology development of the ebaf
tumor marker technology, but shall not as of the date of execution of this
Agreement, supersede the agreement between the parties dated 04 April 2000 and
its extension dated 18 April 2000.
11.0 Severability
The terms of this Agreement are severable. If any term of this Agreement is held
invalid or unenforceable, the valid and enforceable portion of such term and the
remaining provisions of this Agreement will remain in full force and effect. The
remaining contract shall be interpreted consistently with the intent of the
parties with respect to the entire Agreement when the contract was executed.
12.0 Dispute Resolution
12.1. The parties agree that they will use their best efforts to resolve
amicably any dispute arising out of or relating to this Agreement. Any
controversy, claim or dispute that cannot be so resolved shall be settled by
final binding arbitration in accordance with the rules of the American
Arbitration Association and judgment upon the award rendered by the arbitrator
or arbitrators may be entered in any court having jurisdiction thereof. Any such
arbitration shall be conducted in Connecticut. Within one (1) month after the
commencement of the arbitration, each party shall select one person to act as
arbitrator, and the two arbitrators so selected shall select a third arbitrator
within one (1) month of their appointment. The Arbitration Period shall not
exceed three (3) months. Each party shall bear its own costs and expenses and an
equal share of the arbitrator's expenses and administrative fees of arbitration.
12.2. This Agreement shall be governed by and construed in accordance with the
laws of the State of Connecticut, without consideration of choice of law.
13.0. Headings
The headings contained in this Agreement are only for the convenience of the
parties and are not to be construed as a substantive provision and will not in
any manner affect the interpretation of this Agreement.
--9 of 14--
The parties execute this Agreement in accordance with all of the above terms and
conditions.
For Lexon, Inc.:
By: /s/ XXXXXX XXXXXXXX Date: August 2, 2000
---------------------------- ---------------------
Signature
Xxxxxx X. Xxxxxxxx, Xx., M.D.
Medical Director
For DIAGNOSTIC ONCOLOGY CRO, Inc.:
By: /s/ XXXXXX X. XXXXXXX Date: July 17, 2000
---------------------------- ---------------------
Signature
Xxxxxx X. Xxxxxxx
President and Chief Executive Officer
--10 of 14--
ATTACHMENT A. - Estimated Fees, Milestones and Payment
Schedule - Lexon, Inc. - ebaf Technology Assessment and
Development Project
Work to be Performed by DOCRO
1. DOCRO shall assess the technical and clinical performance characteristics
of the currently existing ebaf reagents (raw, partially purified, or
purified ebaf proteins (native or recombinant) or peptides and any antibody
thereto) provided to DOCRO by Xx. X. Xxxxxxxxxx, North Shore University
Hospital, North Shore, New York or LEXON to determine if any ebaf protein
is overexpressed in humans diagnosed with colorectal cancer when compared
to humans diagnosed with a disease other than colorectal cancer or to
apparently healthy, normal humans.
2. If one or more ebaf proteins meets the specifications in 1., above, DOCRO
shall develop and/or refine ebaf antibody and antigen reagents with which
DOCRO shall develop and then characterize a microtiter plate-based enzyme
immunoassay to determine the amount of that particular ebaf protein in the
blood or other fluid matrix of human subjects.
3. DOCRO shall contract with, manage, oversee, and coordinate all other
contractors and subcontractors who provide any material prepared under the
terms of this Agreement.
4. DOCRO shall provide to LEXON on a bi-weekly basis written reports of
DOCRO's progress and recommendations for the next segment of work to be
performed. LEXON must provide written notification to DOCRO within
forty-eight (48) hours of the issuance of the report if LEXON desires DOCRO
not to perform the work that DOCRO recommends in the report.
5. DOCRO shall provide to LEXON a written report summarizing DOCRO's findings
and activities upon DOCRO's completion of the technology assessment portion
of this Agreement and upon termination of this Agreement.
--11 of 14--
Blank Page
--12 of 14--
A. ESTIMATED Milestone and Payment Schedule:
ESTIMATED MILESTONE Payment Made by Lexon
Milestone Completion Date and Received by DOCRO
--------- --------------- ---------------------
1. LEXON and DOCRO EXECUTE CONTRACT/First Payment 28 July 2000 US $ 100,000.00
2. Project Meeting with Xx. Xxxxxxxxxx to Launch Project 11 Aug 2000
3. Transfer of portions of ebaf peptides, proteins, and antibodies 11 Aug 2000
From Xx. Xxxxxxxxxx'x laboratory to DOCRO's laboratory
4. Laboratory Work at DOCRO commences and continues through project 14 Aug 2000
a. Adds second bench staff personnel 28 Aug 2000 US $ 250,000.00
b. Interview and selection of contractor(s) for development and 28 Aug 2000
Production of peptides and polyclonal and monoclonal antibodies
c. Initiate purification of native ebaf 11 Sep 2000
d. Initiate expression cloning of ebaf 11 Sep 2000
e. Acquire fresh frozen tumor and clinical sample sets from ONGOING
colorectal cancer patients
f. Characterize reagents produced by Xx. Xxxxxxxxxx 28 Sept 2000 US $ 200,000.00
- chromatography, electrophoresis/blotting, etc.
g. Testing clinical sample sets (cancer, normal, benign) ONGOING
5. DOCRO and contractor(s) prepare peptides for Mab and Pab contractor(s) 16 Sep 2000
6. DOCRO completes selection and purification of native/recombinant 13 Nov 2000
ebaf proteins, ships sufficient quantities to Mab and Pab contractor(s)
7. DOCRO receives first bleeds of Pab's to peptides; purify/test 20 Nov 2000
--13 od 14--
8. DOCRO receives second bleeds of Pab's to peptides; purify/test 19 Nov 2000 US $ 400,000.00
DOCRO receives first Mab's to peptides; purify/test
9. DOCRO receives first bleeds of Pab's to proteins; purify/test 11 Jan 2001 US $ 400,000.00
DOCRO receives third bleeds of Pabs to peptides; purify/test
10. DOCRO receives second bleeds of Pab's to proteins; purify/test 06 Mar 2001
DOCRO receives first Mab's to proteins; purify/test
11. DOCRO optimizes EIA sandwich assay for the form of ebaf upregulated 11 May 2001
in colon cancer and test clinical samples
12. DOCRO issues written report of findings and recommendations to LEXON 31 May 2001 US $ 145,000.00
13 LEXON makes GO/NO GO decision 15 Jun 2001
------------------------------------------------------------------------------------------------------------------------
TOTAL 10 MONTHS US $1,495,000.00
Comments:
Item 5. - Analysis of Tissue Distribution Data is critical component to this
project.
Item 7. - This assumes the concentration of ebaf is greater than 50 microgram
per gram of colon cancer tissue. If this minimum concentration is not achieved,
this milestone will depend solely upon recombinant ebaf protein produced by/for
Xx. X. Xxxxxxxxxx.
Item 12. - This milestone will be completed, most likely using peptide
polyclonal antibodies.
--14 of 14--
